Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "FDA"

2469 News Found

Alembic Pharma receives USFDA approval for Haloperidol tablets
News | June 06, 2026

Alembic Pharma receives USFDA approval for Haloperidol tablets

The approved product is therapeutically equivalent to Haldol tablets of Ortho McNeil Pharmaceutical


Lupin secures U.S. FDA approval for interchangeable biosimilar Ranibizumab
Drug Approval | June 06, 2026

Lupin secures U.S. FDA approval for interchangeable biosimilar Ranibizumab

Ranluspec is the only interchangeable ranibizumab biosimilar approved in the United States in both vial and pre-filled syringe (PFS) presentations


Aurobindo Pharma receives USFDA nod for generic Tofacitinib tablets
Drug Approval | June 05, 2026

Aurobindo Pharma receives USFDA nod for generic Tofacitinib tablets

Approval for generic version of Xeljanz enables immediate launch and strengthens Aurobindo’s U.S. portfolio with its 586th ANDA approval


FDA fast-tracks Roche’s giredestrant review as data signal potential shift in early breast cancer care
Drug Approval | June 03, 2026

FDA fast-tracks Roche’s giredestrant review as data signal potential shift in early breast cancer care

The filing is backed by Phase III data from the lidERA Breast Cancer study


Lupin and Natco get FDA approval for Eribulin Mesylate injection
Drug Approval | June 03, 2026

Lupin and Natco get FDA approval for Eribulin Mesylate injection

Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials is the bioequivalent to the reference listed drug (RLD) Halaven injection of Eisai, Inc.


Granules Pharmaceuticals receives USFDA EIR for Chantilly facility
News | June 03, 2026

Granules Pharmaceuticals receives USFDA EIR for Chantilly facility

This facility plays an important role in Granules’ global manufacturing and supply network


FDA okays AstraZeneca’s bladder cancer drug Imfinzi Plus BCG
Drug Approval | June 02, 2026

FDA okays AstraZeneca’s bladder cancer drug Imfinzi Plus BCG

First immunotherapy combination approved in the US for BCG-naïve high-risk NMIBC demonstrates a 32% reduction in the risk of disease recurrence, progression, or death


Zydus’ Saroglitazar wins FDA priority review after strong Phase 3 results in liver disease trial
Drug Approval | June 01, 2026

Zydus’ Saroglitazar wins FDA priority review after strong Phase 3 results in liver disease trial

The therapy also delivered significant improvements in key liver enzyme markers


FDA clears Cercare Medical’s CBCT perfusion technology for real-time stroke imaging
Medical Device | June 01, 2026

FDA clears Cercare Medical’s CBCT perfusion technology for real-time stroke imaging

The technology enables clinicians to assess brain tissue and microvascular reperfusion directly in the angiography suite, potentially improving stroke treatment decisions and patient outcomes


Clariant bags FDA nod for bio-based PVC additives
R&D | June 01, 2026

Clariant bags FDA nod for bio-based PVC additives

Derived from rice bran wax, Licocare RBW products offer a renewable solution with a substantially lower carbon footprint than conventional montan waxes